Selected research
Industry Research
Implantable Coronary Drug Eluting Stent Industry Research Report 2026
Market perspective
The global Implantable Coronary Drug Eluting Stent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Implantable Coronary Drug Eluting Stent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Implantable Coronary Drug Eluting Stent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Implantable Coronary Drug Eluting Stent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Implantable Coronary Drug Eluting Stent include Yinyi Biotech, Abbott, Microport Medical, SINOMED, Beijing Amsino Medical, Medtronic, Lepu Medical, Boston Scientific and Terumo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Implantable Coronary Drug Eluting Stent market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Implantable Coronary Drug Eluting Stent Market by Company
Yinyi Biotech
Abbott
Microport Medical
SINOMED
Beijing Amsino Medical
Medtronic
Lepu Medical
Boston Scientific
Terumo
Drug-eluting Stent
Implantable Coronary Drug Eluting Stent Segment by Type
Rapamycin
Everolimus
Paclitaxel
Other
Implantable Coronary Drug Eluting Stent Segment by Application
Angina Pectoris
Myocardial Infarction
Others
Implantable Coronary Drug Eluting Stent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Implantable Coronary Drug Eluting Stent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Implantable Coronary Drug Eluting Stent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Implantable Coronary Drug Eluting Stent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Implantable Coronary Drug Eluting Stent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Implantable Coronary Drug Eluting Stent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Implantable Coronary Drug Eluting Stent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rapamycin
- Everolimus
- Paclitaxel
- Other
Applications
- Angina Pectoris
- Myocardial Infarction
- Others
Companies covered
- Yinyi Biotech
- Abbott
- Microport Medical
- SINOMED
- Beijing Amsino Medical
- Medtronic
- Lepu Medical
- Boston Scientific
- Terumo
- Drug-eluting Stent
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Implantable Coronary Drug Eluting Stent Market Size (2021-2032)
- 2.2.2 Global Implantable Coronary Drug Eluting Stent Sales (2021-2032)
- 2.2.3 Global Implantable Coronary Drug Eluting Stent Market Average Price (2021-2032)
- 2.3 Implantable Coronary Drug Eluting Stent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rapamycin
- 2.3.3 Everolimus
- 2.3.4 Paclitaxel
- 2.3.5 Other
- 2.4 Implantable Coronary Drug Eluting Stent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Angina Pectoris
- 2.4.3 Myocardial Infarction
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Implantable Coronary Drug Eluting Stent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Implantable Coronary Drug Eluting Stent Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Implantable Coronary Drug Eluting Stent Revenue of Manufacturers (2021-2026)
- 3.4 Global Implantable Coronary Drug Eluting Stent Average Price by Manufacturers (2021-2026)
- 3.5 Global Implantable Coronary Drug Eluting Stent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Implantable Coronary Drug Eluting Stent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Implantable Coronary Drug Eluting Stent, Product Type & Application
- 3.8 Global Manufacturers of Implantable Coronary Drug Eluting Stent, Established Date
- 3.9 Global Implantable Coronary Drug Eluting Stent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yinyi Biotech
- 4.1.1 Yinyi Biotech Company Information
- 4.1.2 Yinyi Biotech Business Overview
- 4.1.3 Yinyi Biotech Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yinyi Biotech Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.1.5 Yinyi Biotech Recent Developments
- 4.2 Abbott
- 4.2.1 Abbott Company Information
- 4.2.2 Abbott Business Overview
- 4.2.3 Abbott Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Abbott Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.2.5 Abbott Recent Developments
- 4.3 Microport Medical
- 4.3.1 Microport Medical Company Information
- 4.3.2 Microport Medical Business Overview
- 4.3.3 Microport Medical Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Microport Medical Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.3.5 Microport Medical Recent Developments
- 4.4 SINOMED
- 4.4.1 SINOMED Company Information
- 4.4.2 SINOMED Business Overview
- 4.4.3 SINOMED Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 SINOMED Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.4.5 SINOMED Recent Developments
- 4.5 Beijing Amsino Medical
- 4.5.1 Beijing Amsino Medical Company Information
- 4.5.2 Beijing Amsino Medical Business Overview
- 4.5.3 Beijing Amsino Medical Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Beijing Amsino Medical Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.5.5 Beijing Amsino Medical Recent Developments
- 4.6 Medtronic
- 4.6.1 Medtronic Company Information
- 4.6.2 Medtronic Business Overview
- 4.6.3 Medtronic Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Medtronic Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.6.5 Medtronic Recent Developments
- 4.7 Lepu Medical
- 4.7.1 Lepu Medical Company Information
- 4.7.2 Lepu Medical Business Overview
- 4.7.3 Lepu Medical Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lepu Medical Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.7.5 Lepu Medical Recent Developments
- 4.8 Boston Scientific
- 4.8.1 Boston Scientific Company Information
- 4.8.2 Boston Scientific Business Overview
- 4.8.3 Boston Scientific Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Boston Scientific Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.8.5 Boston Scientific Recent Developments
- 4.9 Terumo
- 4.9.1 Terumo Company Information
- 4.9.2 Terumo Business Overview
- 4.9.3 Terumo Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Terumo Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.9.5 Terumo Recent Developments
- 4.10 Drug-eluting Stent
- 4.10.1 Drug-eluting Stent Company Information
- 4.10.2 Drug-eluting Stent Business Overview
- 4.10.3 Drug-eluting Stent Implantable Coronary Drug Eluting Stent Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Drug-eluting Stent Implantable Coronary Drug Eluting Stent Product Portfolio
- 4.10.5 Drug-eluting Stent Recent Developments
5 Global Implantable Coronary Drug Eluting Stent Market Scenario by Region
- 5.1 Global Implantable Coronary Drug Eluting Stent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Implantable Coronary Drug Eluting Stent Sales by Region: 2021-2032
- 5.2.1 Global Implantable Coronary Drug Eluting Stent Sales by Region: 2021-2026
- 5.2.2 Global Implantable Coronary Drug Eluting Stent Sales by Region: 2027-2032
- 5.3 Global Implantable Coronary Drug Eluting Stent Revenue by Region: 2021-2032
- 5.3.1 Global Implantable Coronary Drug Eluting Stent Revenue by Region: 2021-2026
- 5.3.2 Global Implantable Coronary Drug Eluting Stent Revenue by Region: 2027-2032
- 5.4 North America Implantable Coronary Drug Eluting Stent Market Facts & Figures by Country
- 5.4.1 North America Implantable Coronary Drug Eluting Stent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Implantable Coronary Drug Eluting Stent Sales by Country (2021-2032)
- 5.4.3 North America Implantable Coronary Drug Eluting Stent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Implantable Coronary Drug Eluting Stent Market Facts & Figures by Country
- 5.5.1 Europe Implantable Coronary Drug Eluting Stent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Implantable Coronary Drug Eluting Stent Sales by Country (2021-2032)
- 5.5.3 Europe Implantable Coronary Drug Eluting Stent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Implantable Coronary Drug Eluting Stent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Implantable Coronary Drug Eluting Stent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Implantable Coronary Drug Eluting Stent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Implantable Coronary Drug Eluting Stent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Implantable Coronary Drug Eluting Stent Market Facts & Figures by Country
- 5.7.1 South America Implantable Coronary Drug Eluting Stent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Implantable Coronary Drug Eluting Stent Sales by Country (2021-2032)
- 5.7.3 South America Implantable Coronary Drug Eluting Stent Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Implantable Coronary Drug Eluting Stent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Implantable Coronary Drug Eluting Stent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Implantable Coronary Drug Eluting Stent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Implantable Coronary Drug Eluting Stent Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Implantable Coronary Drug Eluting Stent Sales by Type (2021-2032)
- 6.1.1 Global Implantable Coronary Drug Eluting Stent Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Implantable Coronary Drug Eluting Stent Sales Market Share by Type (2021-2032)
- 6.2 Global Implantable Coronary Drug Eluting Stent Revenue by Type (2021-2032)
- 6.2.1 Global Implantable Coronary Drug Eluting Stent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Implantable Coronary Drug Eluting Stent Revenue Market Share by Type (2021-2032)
- 6.3 Global Implantable Coronary Drug Eluting Stent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Implantable Coronary Drug Eluting Stent Sales by Application (2021-2032)
- 7.1.1 Global Implantable Coronary Drug Eluting Stent Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Implantable Coronary Drug Eluting Stent Sales Market Share by Application (2021-2032)
- 7.2 Global Implantable Coronary Drug Eluting Stent Revenue by Application (2021-2032)
- 7.2.1 Global Implantable Coronary Drug Eluting Stent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Implantable Coronary Drug Eluting Stent Revenue Market Share by Application (2021-2032)
- 7.3 Global Implantable Coronary Drug Eluting Stent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Implantable Coronary Drug Eluting Stent Value Chain Analysis
- 8.1.1 Implantable Coronary Drug Eluting Stent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Implantable Coronary Drug Eluting Stent Production Mode & Process
- 8.2 Implantable Coronary Drug Eluting Stent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Implantable Coronary Drug Eluting Stent Distributors
- 8.2.3 Implantable Coronary Drug Eluting Stent Customers
9 Global Implantable Coronary Drug Eluting Stent Analyzing Market Dynamics
- 9.1 Implantable Coronary Drug Eluting Stent Industry Trends
- 9.2 Implantable Coronary Drug Eluting Stent Industry Drivers
- 9.3 Implantable Coronary Drug Eluting Stent Industry Opportunities and Challenges
- 9.4 Implantable Coronary Drug Eluting Stent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst